Filed by Dexter Corporation
Pursuant to Rule 425 under the Securities
Act of 1933
Subject Company: Dexter Corporation
Commission File No. 001-05542
-------------------------------------------------------------------------------
Important Notice Regarding the SECOND SPECIAL MEETING
------
-------------------------------------------------------------------------------
of Dexter Corporation to be held September 14, 2000
[Dexter Corp. logo]
September 1, 2000
Dear Shareholder:
Your vote has not been received for the special merger meeting of
shareholders of Dexter Corporation to be held at The University Club, One
West 54th Street, New York, New York 10019 on Thursday, September 14, 2000,
at 11:30 a.m., local time. PLEASE KEEP IN MIND THAT THIS IS THE SECOND
DEXTER SPECIAL MEETING FOR WHICH YOU HAVE BEEN ASKED TO VOTE. AT THE FIRST
SPECIAL MEETING ON WEDNESDAY, AUGUST 30, 2000, SHAREHOLDERS OVERWHELMINGLY
APPROVED THE NONWOVENS ASSET SALE TO AHLSTROM PAPER GROUP OY FOR $275
MILLION IN CASH. PLEASE TAKE THE TIME RIGHT NOW TO ENSURE THAT YOUR VOTE IS
CAST AT THIS SECOND IMPORTANT MEETING.
At the meeting you will be asked to approve Dexter Corporation's merger
with Invitrogen Corporation. In the merger, each outstanding share of
Dexter common stock will be converted into $62.50 in cash or Invitrogen
common stock or both. This proposal requires the affirmative vote of the
holders of at least two-thirds of the voting power of all outstanding
shares of Dexter common stock on the August 14, 2000 record date.
YOUR BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED THE MERGER WITH INVITROGEN
AND RECOMMENDS THAT DEXTER STOCKHOLDERS VOTE FOR THE MERGER PROPOSAL
DESCRIBED IN THE MATERIALS PREVIOUSLY SENT TO YOU.
Please vote by Telephone or Internet Today! REMEMBER - EVERY SHARE AND
EVERY VOTE COUNTS! You may also sign, date and mail your duplicate proxy
card in the envelope provided. If you have any questions, please call
MacKenzie Partners, Inc at (800) 322-2885.
Thank you in advance for voting promptly.
Sincerely,
K. Grahame Walker
Chairman and Chief Executive Officer
PLEASE TAKE A MOMENT TO VOTE YOUR SHARES TODAY!
Investors and shareholders are advised to read the joint proxy statement
and prospectus regarding Dexter Corporation's proposed merger with and into
Invitrogen Corporation referenced in the foregoing information, because it
contains important information. The joint proxy statement and prospectus
was filed with the Securities and Exchange Commission by Invitrogen as part
of Invitrogen's registration statement on form S-4, which became effective
August 14, 2000. Investors and shareholders may obtain a free copy of the
joint proxy statement and prospectus and other documents filed by Dexter or
Invitrogen at the Securities and Exchange Commission's web site at
http://www.sec.gov. The joint proxy statement and prospectus and such other
documents also may be obtained by directing such request to Dexter
Corporation, One Elm Street, Windsor Locks, Connecticut 06906,
860-292-7675.
